- Book
- January 2024
- 864 Pages
- Book
- December 2023
- 864 Pages
- Book
- April 2023
- 128 Pages
- Book
- April 2023
- 176 Pages
- Book
- September 2021
- 304 Pages
- Book
- May 2021
- 512 Pages
- Book
- October 2020
- 288 Pages
- Book
- October 2020
- 600 Pages
- Book
- December 2019
- 432 Pages
- Book
- December 2019
- 432 Pages
- Book
- November 2019
- 432 Pages
- Book
- November 2019
- 432 Pages
- Book
- October 2019
- 632 Pages
- Book
- January 2019
- 600 Pages
- Book
- April 2018
- 776 Pages
United States
- Book
- January 2016
- 368 Pages
- Book
- January 2016
- 952 Pages
- Book
- August 2015
- 288 Pages
- Book
- April 2013
- 294 Pages
- Book
- April 2013
- 256 Pages

Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies.
The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments.
Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more